A recent report reveals that the growth in prevalence of chronic diseases and rise in patient preference for advanced drug-delivery systems are driving the global smart drug-delivery systems market. In particular, it points to products that facilitate self-medication gaining traction as medical technology developers attempt to make their offerings more patient-centric.

The report, “Smart Drug Delivery Systems Market” published by Transparency Market Research, forecasts the market to “flourish” at a CAGR of 15.2 percent from 2022 to 2031, increasing to a value of $36 billion. As of 2023, a valuation of $9.2 billion is projected for the smart drug-delivery systems market.

“Drug formulators focusing on therapeutic areas need to pay close attention to patient experience in order to optimize adherence,” the report says. “Reduced dosage frequency and improved ease of administration are critical to providing the best possible experience for patients and encouraging adherence to their treatment regimen.”

According to the report, patient preference is shifting toward controlled drug-delivery systems, as the healthcare sector’s digitalization accelerates through the gradual integration of diagnostic point-of-care sensors and connected computation platforms into patients’ daily routines. Metered dose inhalers, nebulizers, and dry powder inhalers are used for pulmonary drug delivery.

The analysts note that market players are developing products that help ensure that drugs achieve the desired therapeutic levels while avoiding the need for frequent administration. This enables patients to adhere to their drug regimens and thus improve compliance. For example, in March 2022, Novo Nordisk A/S launched the NovoPen 6 and NovoPen Echo Plus smart connected insulin pens available by prescription in the United Kingdom for people with diabetes who use Novo Nordisk insulin.

The connected wearable injectors segment held the largest share of the market in 2021 and is expected to maintain its dominance. “Growth of the segment can be ascribed to the rise in concerns over needle stick injuries, surge in geriatric population and prevalence of chronic diseases, and increase in demand for continuous health monitoring.

The connected autoinjectors segment is likely to grow significantly during the forecast period. Market players are launching new connected autoinjectors that improve patient experience.

Sherrie Trigg

Editor and Director of Medical Content

A copy of the report is available below.

Document cover
Emerging Trends in Drug Delivery

Download this free supporting PDF from SAE MEdia Group!

Don't have an account?

Topics:
Drug Delivery Drug Delivery Market Reports Medical

More From SAE Media Group

    Magazine cover
    Medical Design Briefs Magazine

    This article first appeared in the August, 2023 issue of Medical Design Briefs Magazine (Vol. 13 No. 8).

    Read more articles from this issue here.

    Read more articles from the archives here.

    Overview

    The document discusses emerging trends in drug delivery systems, highlighting the importance of innovation in this field to enhance patient outcomes and therapeutic effectiveness. It emphasizes that advancements in drug delivery mechanisms are crucial as medicines evolve, necessitating efficient development and access to published information in scientific literature and patents.

    The document outlines the historical context of pharmaceutical activities related to drug delivery systems from 2004 to 2018, categorizing them into oral, parenteral, and topical delivery systems. It notes that the leading pharmaceutical activities in these categories are often linked to shifts in therapeutic research focus, with a particular emphasis on antitumor, anti-inflammatory, and antiviral agents across various delivery methods. For instance, oral delivery systems have been prominent in areas such as oral hygiene and dietary supplements, while parenteral systems have been significant for vaccines and dermatological agents.

    The document also highlights the challenges faced by organizations in monitoring the rapidly changing landscape of drug delivery. It points out that traditional search tools, such as government patent office websites and general search engines, often lack precision and comprehensive coverage, making it difficult to find relevant information in specialized areas like formulations and polymers. As a result, many innovation-focused organizations invest in high-quality, specialized platforms like CAS SciFinder Discovery Platform and STN IP Protection Suite, which provide comprehensive oversight of global publications and patents.

    Furthermore, the document stresses the importance of adopting effective monitoring strategies to stay updated on new discoveries and trends. It warns that failing to do so could lead to wasted resources on redundant research and missed opportunities in the competitive landscape. By keeping abreast of the latest developments, organizations can gain insights into emerging areas of opportunity and competitor strategies, guiding their own innovation efforts.

    In summary, the document serves as a call to action for researchers and companies in the drug delivery field to leverage advanced monitoring tools and stay informed about the latest trends and technologies to maintain a competitive edge and drive future innovations in healthcare.